The time when pharma fully embraces tech is still very far off, despite some optimistic comments from executives at JPM. So far, in fact, “no one can see it at the moment,” one expert told us. It’s more likely that
read moreIf so, you ought to know that the 2018 PharmaTimes Clinical Researcher of the Year – The Americas application process for teams has been made MUCH simpler this year, so if you thought you didn’t have enough time to enter, think
read moreCost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis. More: NICE backs wider use of MSD’s Simponi Source: News
read moreEuropean regulators have expanded the scope of Vertex’ Orkambi to include children with cystic fibrosis aged six through 11 who have two copies of the F508del mutation. More: Vertex’ CF therapy Orkambi cleared for younger patients Source: News
read moreA combination therapy being developed by MSD and Eisai for kidney cancer has been awarded Breakthrough Designation in the US. More: US ‘breakthrough’ badge for MSD/Eisai cancer combo Source: News
read moreMSD has launched Zinplava in the UK, offering patients a novel therapeutic option for the prevention of Clostridium difficile recurrence. More: MSD launches Clostridium difficile antitoxin in the UK Source: News
read more© 1994 - 2024 B.M. Pharmaceuticals